- POSITIVE
Quarterly Revenue Rossari Biotech Sep-2026 Quarterly Revenue is Rs 497 Cr which is growth of 18.1% YoY.
- POSITIVE
Quarterly Net Profit Rossari Biotech Sep-2026 Quarterly Net Profit is Rs 34 Cr which is growth of 9.5% YoY.
NSE: ROSSARI | BSE: 543213
Rossari Biotech Live Share Price Today, Share Analysis and Chart
aboutRossari Biotech Ltd. is an Indian specialty chemical manufacturer providing sustainable chemical solutions across multiple industries. The company operates through three primary business segments: Home, Personal Care and Performance Chemicals (HPPC),... Read More
399.25-8.35(-2.05%)
52,882
NSE+BSE Volume
NSE 30 Oct, 2026 3:31 PM (IST)
Slowing Down StockThese stocks have medium financials and valuations, but weak momentum indicating decreasing investor interestView SimilarEmbed DVM
Please subscribe to view forecaster data
Rossari Biotech Stock Price Analysis
Day Price Range-2.0% 1 Day return | 399.2 (LTP) 395412 LowHigh |
|---|---|
Week Price Range-3.7% 1 Week return | 399.2 (LTP) 395417 LowHigh |
Month Price Range-4.5% 1 Month return | 399.2 (LTP) 395459.8 LowHigh |
52 Week Price Range-37.7% 1 Year return | 399.2 (LTP) 375654 LowHigh |
Rossari Biotech Forecaster - Analyst Share Price Target and Estimates
Revenue forecast
EPS forecast
CURRENT EPS
AVG. ESTIMATE
Consensus Recommendation
4 ANALYST Recommendations
BUY
Forecaster is a Premium Feature
You need to upgrade your subscription plan to access this feature
See what you get Forecaster
Competitors/Peers
Quarterly
Annual
Balance Sheet
Ratios
Cash Flow
Documents
Rossari Biotech quarterly results: revenue, profit, and P&L – 13 quarter history
Nested row level
Base Level
Reporting Type
Standalone
Cell Data
Actual
Table Settings
YoY & New to Old
Nested row level
Base Level
Export
| Indicator | Graph | Sep '26 | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 497 | 484.5 | 538.9 | 451.8 | 420.9 | 367.5 | 429.1 | 369.3 | 337.1 | 302 | 315.2 | 300.9 | 334 | ||
Operating Exp. | 438 | 425.9 | 452.5 | 400.3 | 369.1 | 321.8 | 374.5 | 318.3 | 291.7 | 260.9 | 272.1 | 257.6 | 289.7 | |
Operating Profit | 57.3 | 56.4 | 63.6 | 50.4 | 50.4 | 43.9 | 52.2 | 50 | 44.3 | 39.8 | 41.7 | 41.1 | 42.3 | |
Operating Profit Margin % | 11.56% | 11.70% | 12.32% | 11.18% | 12.02% | 12.01% | 12.23% | 13.57% | 13.18% | 13.24% | 13.30% | 13.77% | 12.75% | |
Depr. | 10.7 | 8.3 | 9 | 7.5 | 7.3 | 7.2 | 7.7 | 7.4 | 6.5 | 6.1 | 6.6 | 5.8 | 6.3 | |
Interest | 2.1 | 3.8 | 3.8 | 4 | 2.5 | 3.1 | 3.1 | 2.3 | 1.9 | 2.3 | 1.7 | 2.6 | 2.5 | |
Profit Before Tax | 46.2 | 46.4 | 73.6 | 40.1 | 42 | 35.4 | 43.9 | 41.3 | 36.9 | 32.7 | 34.7 | 34.8 | 35.5 | |
Tax | 11.9 | 12.2 | 18.8 | 9.5 | 10.7 | 9.2 | 11.5 | 10.6 | 9.5 | 8.3 | 8.6 | 9.3 | 9.1 | |
Net Profit | 34.2 | 34.3 | 54.7 | 30.6 | 31.3 | 26.2 | 32.4 | 30.6 | 27.4 | 24.3 | 26.2 | 25.5 | 26.4 | |
EPS Adj. latest | 6.2 | 6.2 | 9.9 | 5.5 | 5.6 | 4.7 | 5.8 | 5.5 | 5 | 4.4 | 4.7 | 4.6 | 4.8 | |
Net profit TTM | 153.9 | 150.9 | 142.8 | 120.5 | 120.5 | 116.7 | 114.7 | 108.6 | 103.5 | 102.4 | 99.6 | 96.6 | 88.5 | |
Basic EPS TTM | 27.8 | 27.2 | 25.8 | 21.8 | 21.8 | 21.1 | 20.7 | 19.6 | 18.7 | 18.5 | 18 | 17.5 | 16 | |
Earnings Transcripts | ||||||||||||||
AI Summary | ||||||||||||||
Results PDF | ||||||||||||||
Result Notes |
*All financials are in INR Cr and price data in INR
Add metric to table
Search...
Rossari Biotech Technical Analysis
Rossari Biotech EMA & SMA
Bearish-8
0 bullish, 8 bearish
Bullish0
Bearish8
| 5 Day | 407.2 |
|---|---|
| 10 Day | 413.4 |
| 12 Day | 415.3 |
| 20 Day | 421.7 |
| 26 Day | 426.3 |
|---|---|
| 50 Day | 443.4 |
| 100 Day | 466.8 |
| 200 Day | 500.8 |
Rossari Biotech Delivery And Volume
Daily Avg. Delivery Volume %
30 Oct, 202657.8%
Week59.7%
Month54.5%
Rossari Biotech Active Candlesticks
Hikkake Uptrend
Legend
Positive IndicatorNeutral IndicatorNegative Indicator
Rossari Biotech Resistance and Support
402.08
Pivot
| First Resistance | 409.2 |
|---|---|
| Second Resistance | 419.1 |
| Third Resistance | 426.2 |
| First Support | 392.2 |
|---|---|
| Second Support | 385.1 |
| Third Support | 375.2 |
| Day RSI | 35.5 |
|---|---|
| Day MACD | -11 |
| Day MFI | 44.8 |
| Day MACD Signal Line | -9.8 |
Rossari Biotech Beta
| 1 Month | 0.5 |
|---|---|
| 1 Year | 1.2 |
| 3 Month | 0.8 |
|---|---|
| 3 Year | 0.8 |
Rossari Biotech Price Change Analysis
↓-4.5%
Over 1 Month
LowHigh
395459.8
↓-20.8%
Over 3 Months
LowHigh
395540.0
↓-16.6%
Over 6 Months
LowHigh
395575
↓-37.7%
Over 1 Year
LowHigh
375654
Rossari Biotech Deals - Insider, Bulk, Block and SAST
| Client Name | Deal Type | Action | Date | Avg. Price | Quantity | Exchange |
|---|---|---|---|---|---|---|
| BHUPESH KUMAR LODHA | Bulk | Purchase | 30 Apr 2026 | 491.50 | 298,000 | NSE |
| GOLDMAN SACHS INDIA FUND LIMITED | Block | Sell | 20 Sep 2021 | 1478.65 | 666,135 | BSE |
| GOLDMAN SACHS FUNDS GOLDMAN SACHS INDIA EQUITY PORTFOLIO | Block | Purchase | 20 Sep 2021 | 1478.65 | 666,135 | BSE |
| IIFL SPECIAL OPPORTUNITIES FUND SERIES 4 | Block | Sell | 19 Jul 2021 | 1249.50 | 166,875 | NSE |
| PUBLIC SECTOR PENSION INVESTMENT BOARD | Block | Purchase | 19 Jul 2021 | 1249.50 | 166,875 | NSE |
| PLUTUS WEALTH MANAGEMENT LLP | Bulk | Purchase | 02 Sep 2020 | 773.82 | 300,000 | NSE |
| TWO ROADS TRADING PRIVATE LIMITED | Bulk | Sell | 27 Jul 2020 | 718.07 | 280,400 | NSE |
| TWO ROADS TRADING PRIVATE LIMITED | Bulk | Purchase | 27 Jul 2020 | 717.68 | 280,400 | NSE |
| VAIBHAV STOCK AND DERIVATIVES BROKING PRIVATE LIMITED | Bulk | Sell | 24 Jul 2020 | 758.44 | 307,496 | NSE |
| VAIBHAV STOCK AND DERIVATIVES BROKING PRIVATE LIMITED | Bulk | Purchase | 24 Jul 2020 | 758.13 | 307,496 | NSE |
Rossari Biotech Corporate Actions
Rossari Biotech Dividend history and yield
Rossari Biotech dividend yields, including actual and adjusted, and dividend history, including announcement, record, and ex-dividend dates. Track Rossari Biotech dividend yield over time.
#Ex-Date | Dividend Amount | Dividend Type | Record Date | Instrument Type |
|---|---|---|---|---|
110 Jul 2026 | 0.5 | FINAL | 10 Jul 2026 | Equity Share |
220 Jun 2025 | 0.5 | FINAL | 20 Jun 2025 | Equity Share |
316 Aug 2024 | 0.5 | FINAL | - | Equity Share |
424 May 2023 | 0.5 | FINAL | - | Equity Share |
507 Jul 2022 | 0.5 | FINAL | - | Equity Share |
Rossari Biotech Board Meetings
Rossari Biotech past and upcoming board meetings.
#Ex-Date | Purpose | Notes |
|---|---|---|
117 Oct 2026 | Quarterly Results | - |
218 Jul 2026 | Quarterly Results | - |
327 Apr 2026 | Audited Results & Final Dividend | - |
417 Jan 2026 | Quarterly Results | - |
515 Oct 2025 | Quarterly Results | - |
Rossari Biotech Research Reports
Rossari Biotech research reports with share price targets, and buy/hold/sell recommendations from top brokers.
# Date | Broker Name | Target | Price When Recommended | Type | Upside | Change Since Recommendation | Links |
|---|---|---|---|---|---|---|---|
| 125 Oct 2026 | Deven Choksey | 472 | 406.35 | Accumulate | 16.16% | -1.75% | |
| 219 Oct 2026 | ICICI Securities Limited | 520 | 437.5 | Buy | 18.86% | -8.74% | |
| 320 Jul 2026 | ICICI Securities Limited Target | 605 | 518.55 | Buy | 16.67% | -23.01% | |
| 420 Jul 2026 | Deven Choksey Reco Target | 561 | 518.55 | Accumulate | 8.19% | -23.01% | |
| 529 Apr 2026 | Deven Choksey | 604 | 467 | Buy | 29.34% | -14.51% |
Rossari Biotech Corporate Filings
Rossari Biotech BSE corporate filings and AGM, press releases, insider trading & SAST, results and corporate actions.
| Date | Announcement Title | Details | Links |
|---|---|---|---|
| 22 Oct 2026 | Rossari Biotech Ltd - 543213 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript | Intimation of Transcript of Q2 & H1 FY27 for the Earnings Conference Call held on October 19, 2026 | |
| 19 Oct 2026 | Rossari Biotech Ltd - 543213 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome | Audio recording of Earnings Conference Call for Q2 & H1 FY 27. | |
| 19 Oct 2026 | Q2FY27 Quarterly Result Announced for Rossari Biotech Ltd. | Specialty Chemicals company Rossari Biotech announced Q2FY27 results Standalone Financial Highlights: Revenue from operations: Reached Rs 4,952.76 million in 'Q2FY27', representing an 18.06% YoY increase from Rs 4,195.12 million in 'Q2FY26', and a 2.70% QoQ growth from Rs 4,822.75 million in 'Q1FY27'. Total Income: Stood at Rs 4,969.62 million in 'Q2FY27', reflecting a YoY increase of 18.07% from Rs 4,209.09 million in 'Q2FY26', and a QoQ rise of 2.58% from Rs 4,844.63 million in 'Q1FY27'. Profit before Tax: Recorded at Rs 461.53 million in 'Q2FY27', indicating a 9.96% YoY growth from Rs 419.72 million in 'Q2FY26', but a marginal QoQ decline of 0.58% from Rs 464.21 million in 'Q1FY27'. Net Profit after Tax (PAT): Achieved Rs 342.31 million in 'Q2FY27', marking a 9.54% YoY increase from Rs 312.49 million in 'Q2FY26', and a slight QoQ decrease of 0.10% from Rs 342.66 million in 'Q1FY27'. For 'H1FY27', PAT stood at Rs 684.97 million. Consolidated Financial Highlights: Revenue from operations: Reached Rs 6,975.60 million in 'Q2FY27', demonstrating a YoY growth of 19.02% from Rs 5,861.07 million in 'Q2FY26', and remaining relatively flat QoQ with a 0.05% increase from Rs 6,972.00 million in 'Q1FY27'. Total Income: Stood at Rs 6,981.59 million in 'Q2FY27', showing an 18.79% YoY increase from Rs 5,877.11 million in 'Q2FY26', and a QoQ drop of 0.32% from Rs 7,003.87 million in 'Q1FY27'. Profit before Tax: Recorded at Rs 492.69 million in 'Q2FY27', representing a slight YoY decline of 0.81% from Rs 496.72 million in 'Q2FY26', but a 3.35% QoQ increase from Rs 476.72 million in 'Q1FY27'. Net Profit after Tax (PAT): Achieved Rs 389.07 million in 'Q2FY27', reflecting a 5.51% YoY growth from Rs 368.76 million in 'Q2FY26', and a QoQ increase of 10.86% from Rs 350.95 million in 'Q1FY27'. For 'H1FY27', consolidated PAT reached Rs 740.02 million. Business Highlights: Greenfield Expansion: The Board accorded its approval for the leasing of land by Rossari International Limited Company, a wholly-owned subsidiary, to set up a greenfield manufacturing facility in the Kingdom of Saudi Arabia (KSA). Stock Options: During the quarter ended September 30, 2026, the Parent Company allotted 2,500 equity shares of Rs 2 each pursuant to the exercise of options under the approved Rossari Employee Stock Option Plan - 2019. Segment Reporting: The Group deals in Specialty chemicals and considering that the nature of products and the predominant risk and returns of the products are similar, the Group considers it as one operating segment. Edward Menezes, Promoter & Executive Chairman, & Sunil Chari, Promoter & Managing Director, said: “We delivered robust consolidated growth of 19% YoY in Q2FY27, achieving a record quarterly revenue of Rs 698 crore. The performance was driven by healthy momentum in the domestic business and the continued expansion of our international presence. We concluded the first half of FY27 on a strong note, with consolidated revenue of Rs 1,395 crore in H1FY27, a healthy growth of 23% YoY. The growth was broad-based, led by healthy volume, improved product mix and focused execution across our businesses. During Q2FY27, the HPPC, TSC and AHN businesses delivered YoY growth of 18%, 26% and 11%, respectively. Performance was supported by a higher contribution from value-added products and improved wallet share with customers across end-user industries. We continue to operate under dynamic business environment marked by raw material volatility, geopolitical uncertainty and cautious customer behaviour. Despite of these headwinds in Q2FY27 we maintained the gross margin at ~32% level and EBITDA margin at ~12.5% level. During H1FY27, we made progress in strengthening our balance sheet and improving cash flow generation. Our net working capital cycle improved to 86 days as of 30 September 2026, compared with 97 days as of 31 March 2026. Further, net debt declined to Rs 221 crore from Rs 281 crore over the same period. We are pleased to announce that the Board has approved the leasing of land to Rossari International Limited Company (RILC), our wholly owned subsidiary, for setting up a greenfield manufacturing facility in the Kingdom of Saudi Arabia (KSA). This builds on the in-principle approval granted by the Board earlier and marks a key milestone in Rossari’s international growth journey. Our strategic initiatives are progressing in the right direction. These include monetising non-core assets, rationalising lower-margin businesses and improving the product mix. We remain confident that operating leverage, scale benefits and these initiatives will support progressive improvement in profitability. With strong R&D; capabilities, expanding capacities, a healthy balance sheet and a growing global footprint, we are well placed to build an integrated, intelligent and impactful specialty chemicals platform and deliver sustained long-term growth.” Result PDF | |
| 18 Oct 2026 | Rossari Biotech Ltd - 543213 - Announcement under Regulation 30 (LODR)-Press Release / Media Release | Press Release for Q2 FY27 Results | |
| 18 Oct 2026 | Rossari Biotech Ltd - 543213 - Announcement under Regulation 30 (LODR)-Investor Presentation | Intimation of Q2 & H1 FY27- Earnings Presentation |
Rossari Biotech Documents
Rossari Biotech Earnings Call
Rossari Biotech earnings calls, including management commentary and AI-generated summaries.
| Date | Title | Links |
|---|---|---|
| 19 Oct 2026 | Rossari Biotech Ltd - 543213 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome | Link |
| 04 May 2026 | Rossari Biotech Ltd - 543213 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript | Link |
| 23 Jan 2026 | Rossari Biotech Ltd - 543213 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript | Link |
| 27 Oct 2025 | Rossari Biotech Ltd - 543213 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript | Ai summaryLink |
| 25 Jul 2025 | Rossari Biotech Ltd - 543213 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript | Ai summaryLink |
Rossari Biotech Annual Reports
Rossari Biotech financials, including annual results, balance sheets, and cash flow statements.
Rossari Biotech Credit Ratings
Rossari Biotech credit ratings from CRISIL and leading rating agencies, assessing financial stability, investment grade, and related PDF documentation.
| Date | Rating Agency | Company Name | Description | Links |
|---|---|---|---|---|
| 06 May 2026 | icra ratings | Rossari Biotech Limited | Update on Material Event | Link |
| 03 Dec 2025 | icra ratings | Rossari Biotech Limited | Ratings reaffirmed and assigned for enhanced amount | Link |
| 23 Oct 2024 | icra ratings | Rossari Biotech Limited | Ratings reaffirmed; outlook revised to positive | Link |
| 08 Sep 2022 | icra ratings | Rossari Biotech Limited | Rossari Biotech Limited: Ratings reaffirmed | Link |
| 25 Jul 2021 | icra ratings | Rossari Biotech Limited | Rossari Biotech Limited- Update on Material Event | Link |
Rossari Biotech Investor Presentations
Rossari Biotech investor presentations, including business updates, financial insights, and strategic initiatives.
| Date | Report Title | Links |
|---|---|---|
| 19 Jul 2026 | Rossari Biotech Ltd - 543213 - Announcement under Regulation 30 (LODR)-Investor Presentation | Link |
| 28 Apr 2026 | Rossari Biotech Ltd - 543213 - Announcement under Regulation 30 (LODR)-Investor Presentation | Link |
| 18 Jan 2026 | Rossari Biotech Ltd - 543213 - Announcement under Regulation 30 (LODR)-Investor Presentation | Link |
| 16 Oct 2025 | Rossari Biotech Ltd - 543213 - Announcement under Regulation 30 (LODR)-Investor Presentation | Link |
| 20 Jul 2025 | Rossari Biotech Ltd - 543213 - Announcement under Regulation 30 (LODR)-Investor Presentation | Link |
Rossari Biotech - Company Profile
Rossari Biotech Management Structure
Rossari Biotech management structure with salaries, total experience, and qualifications.
Rossari Biotech Board of Directors
Rossari Biotech Board of directors with salaries, total experience, and qualifications.
Website: www.rossari.com
About the company - Business Profile
Rossari Biotech Ltd. is an Indian specialty chemical manufacturer providing sustainable chemical solutions across multiple industries. The company operates through three primary business segments: Home, Personal Care and Performance Chemicals (HPPC), Textile Specialty Chemicals (TSC), and Animal Health and Nutrition (AHN). With over 25 years of experience, Rossari has established a strong market position as an agile and innovation-driven player in the specialty chemicals space.
Key Points
- Key Facts:
- Incorporated: March 2003 (converted into a joint stock company in 2009).
- Headquarters: Mumbai, Maharashtra.
- Stock Listing: Listed on BSE and NSE.
- Global Presence: Exports to over 65 countries.
- Operations and Resources:
- Manufacturing Facilities: Operates 7 manufacturing facilities with a total installed capacity of 3,67,100 MTPA (including Unitop Chemicals and Tristar Intermediates).
- R&D Capabilities: Maintains 4 R&D facilities. A new R&D facility was recently established at Koparkhairane, Navi Mumbai.
- Product Portfolio: Over 4,300 products serving more than 3,010 customers.
- Business Model and Strengths:
- Rossari follows a B2B and B2B2C business model, focusing on customized specialty chemical solutions.
- It excels in rapid product development and scaling, supported by an "asset-light" expansion strategy through acquisitions like Unitop Chemicals, Tristar Intermediates, and Romakk Chemicals.
- Revenue Breakdown (FY 2024-25):
- Total Consolidated Revenue: ₹2,080.3 crore.
- By Segment:
- HPPC: 76% (₹1,581 crore)
- TSC: 18% (₹374.4 crore)
- AHN & Others: 6% (₹124.8 crore)
- Financial Highlights (FY 2025 vs FY 2026):
- FY 2025 Revenue: ₹2,080.3 crore.
- FY 2026 Revenue: ₹2,396.4 crore (15.2% Y-o-Y growth).
- FY 2026 EBITDA: ₹286.0 crore (Margin: 11.9%).
- FY 2026 PAT: ₹138.3 crore (Consolidated).
- Innovation and Strategic Initiatives:
- Sustainable Chemicals: Focus on eco-friendly products like silicones, enzymes, and bio-based surfactants.
- Expansion: Establishing a new vitamin premix and minerals facility and expanding presence in Russia, Vietnam, and the Philippines.
- Digitalization: Deployment of advanced ERP systems for supply chain optimization.
- Workforce:
- Total Workforce: 2,681 employees (as of March 2025).
- Diversity: 202 women in the workforce; 50% women representation among Independent Directors.
- Major Subsidiaries:
- Unitop Chemicals Pvt. Ltd.
- Tristar Intermediates Pvt. Ltd.
- Buzil Rossari Pvt. Ltd. (BRPL).
- Rossari Consumer Products Pvt. Ltd. (RCPPL).
